Denne side blev automatisk oversat, og nøjagtigheden af oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer

21. august 2013 opdateret af: Hospital Authority, Hong Kong

Randomized Trial to Evaluate the Therapeutic Gain by Changing the Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and the Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma

The objectives of this clinical study are threefold:

To compare the benefits in cancer control and survival obtained from adding induction-concurrent chemotherapy to radiation with those from adding concurrent-adjuvant chemotherapy to radiation.
To test whether replacing fluorouracil with Xeloda in combining with cisplatin (PF or PX, respectively) in the chemotherapy plan will maintain or improve further the chemotherapy benefits while reducing the duration of hospital stay.
To see if accelerated fractionation radiotherapy can improve the outcome of patients as compared with conventional fractionation radiotherapy.

Studieoversigt

Status

Ukendt

Betingelser

Nasopharyngeale neoplasmer

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

798

Fase

Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Kina
- - Hong Kong, Kina
    - Queen Elizabeth Hospital
  - Hong Kong, Kina
    - Prince of Wales Hospital
  - Hong Kong, Kina
    - Queen Mary Hospital
  - Hong Kong, Kina
    - Tuen Mun Hospital
  - Hong Kong, Kina
    - Pamela Youde Nethersole Eastern Hospital
  - Hong Kong, Kina
    - Princess Margaret Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

N/A

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Histologically proven nasopharyngeal carcinoma
Non-keratinizing or undifferentiated type Stage III-IVB (by AJCC/UICC 6th edition)
Essential staging investigations: CT or MRI of nasopharyngeal region Chest x-ray (or CT thorax)
Liver function test, alkaline phosphatase Liver and bone scan if alkaline phosphatase exceeds the institutional upper limit of normal, or if clinically indicated.
Liver scan if SGOT exceeds the institutional upper limit of normal
Adequate marrow: WBC > 4 and platelet > 100
Adequate renal function: creatinine clearance > 60 ml/min.
Satisfactory performance status: > 2 by ECOG System.

Exclusion Criteria:

WHO Type I squamous cell carcinoma or adenocarcinoma
Age > 70
Treatment with palliative intent (including those with tumor extent mandating the use of AP opposing facio-cervical field technique)
Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer for which the patient has been disease-free for five years.
Pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period).
History of previous RT (except for non-melanomatous skin cancers outside intended RT treatment volume).
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Primært formål: Behandling
Tildeling: Randomiseret
Interventionel model: Faktoriel opgave
Maskning: Ingen (Åben etiket)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål	Tidsramme
Progression-free survival Tidsramme: 5-year	5-year
Overall Survival Tidsramme: 5-year	5-year

Sekundære resultatmål

Resultatmål	Tidsramme
Overall / Locoregional / Distant Failure Free Rate Tidsramme: 5-year	5-year
Chemotherapy and RT toxicity Tidsramme: within 90 day from commencement of RT	within 90 day from commencement of RT
Late Toxicity Tidsramme: 5-year	5-year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Hospital Authority, Hong Kong

Samarbejdspartnere

Hong Kong Nasopharyngeal Cancer Study Group Limited

Efterforskere

Ledende efterforsker: Anne WM Lee, Cos, Clinical Oncology, Pamela Youde Nethersole Eastern Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

HAREC Clinical Trial Registry

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2006

Studieafslutning (Forventet)

1. august 2013

Datoer for studieregistrering

Først indsendt

18. december 2007

Først indsendt, der opfyldte QC-kriterier